Prognostic Models for Early and Late Tumor Progression Prediction in Nasopharyngeal Carcinoma: An Analysis of 8292 Endemic Cases

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 Oct 27

PMID 36301691

Authors

Lu-Lu Zhang

Wei-Hong Zheng

Wei-Jie Zhu

Qi-Ling Deng

Jun-Ling Peng

Yi-Yang Li

Ying Sun

Li Lin

Affiliations

Soon will be listed here.

Abstract

Objectives: The time for posttreatment tumor progression differs between nasopharyngeal carcinoma (NPC) patients. Herein, we established effective nomograms for predicting early tumor progression (ETP) and late tumor progression (LTP) in NPC patients.

Methods: We retrospectively enrolled 8292 NPC patients (training cohort: n = 6219; validation cohort: n = 2073). The ELP and LTP were defined as the time to tumor progression ≤24 and >24 months after treatment, respectively.

Results: The ETP and LTP accounted for 52.6 and 47.4% of the total patient cohort, respectively. Patients who developed ETP had markedly worse overall survival (OS) versus patients who suffered from LTP (5-year OS: 26.2% vs. 59.7%, p < 0.001). Further, we identified 10/6 predictive factors significantly associated with ETP/LTP via logistic regression analyses. These indicators were used separately to construct two predictive nomograms for ETP and LTP. In the training group, the ETP nomogram [Harrell Concordance Index (C-index) value: 0.711 vs. 0.618; p < 0.001] and LTP nomogram (C-index value: 0.701 vs. 0.612; p < 0.001) were significantly superior for risk stratification than the TNM staging. These results were supported in the validation group with a C-index value of 0.753 and 0.738 for the ETP and LTP nomograms, respectively. High-risk patients defined by ETP/LTP nomograms had shorter progression-free survival than low-risk patients (all p < 0.001).

Conclusion: The established nomograms can help in ELP or LTP risk stratification for NPC patients. Our current results might also provide insights into individualized treatment decisions and designing surveillance strategies for NPC patients.

Citing Articles

Prediction of Persistent Tumor Status in Nasopharyngeal Carcinoma Post-Radiotherapy-Related Treatment: A Machine Learning Approach.

Tseng H, Shen C, Kao P, Chuang C, Yan D, Liao Y Cancers (Basel). 2025; 17(1.

PMID: 39796725 PMC: 11720740. DOI: 10.3390/cancers17010096.

Early recurrence as a pivotal event in nasopharyngeal carcinoma: identifying predictors and key molecular signals for survivors.

Li Y, Huang Z, Zeng X, Pan Y, Wu L, Wang J Head Face Med. 2024; 20(1):55.

PMID: 39342276 PMC: 11438418. DOI: 10.1186/s13005-024-00457-7.

Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases.

Zhang L, Zheng W, Zhu W, Deng Q, Peng J, Li Y Cancer Med. 2022; 12(5):5384-5396.

PMID: 36301691 PMC: 10028159. DOI: 10.1002/cam4.5361.

References

Guo R, Tang L, Mao Y, Du X, Chen L, Zhang Z . Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2018; 125(1):79-89. DOI: 10.1002/cncr.31741. View

Modvig L, Vase M, DAmore F . Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2017; 179(1):75-82. DOI: 10.1111/bjh.14822. View

Courdi A, Largillier R, Ferrero J, Lallement M, Raoust I, Ettore F . Early versus late local recurrences after conservative treatment of breast carcinoma: differences in primary tumor characteristics and patient outcome. Oncology. 2007; 71(5-6):361-8. DOI: 10.1159/000107771. View

Wu L, Zhang X, Xie X, Lu Y, Wu J, He X . Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. Oral Oncol. 2019; 98:141-146. DOI: 10.1016/j.oraloncology.2019.09.029. View

Colevas A, Yom S, Pfister D, Spencer S, Adelstein D, Adkins D . NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018; 16(5):479-490. DOI: 10.6004/jnccn.2018.0026. View

Zhang L, Zheng W, Zhu W, Deng Q, Peng J, Li Y . Prognostic models for early and late tumor progression prediction in nasopharyngeal carcinoma: An analysis of 8292 endemic cases. Cancer Med. 2022; 12(5):5384-5396. PMC: 10028159. DOI: 10.1002/cam4.5361. View

Zhao L, Zhou B, Shi M, Wang J, Xiao F, Xu M . Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China. Oral Oncol. 2012; 48(9):864-9. DOI: 10.1016/j.oraloncology.2012.03.001. View

Zhang L, Zhou G, Li Y, Tang L, Mao Y, Lin A . Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study. Cancer Med. 2017; 6(12):2822-2831. PMC: 5727247. DOI: 10.1002/cam4.1233. View

Long G, Tang W, Fu X, Liu D, Zhang L, Hu G . Pre-treatment Serum Lactate Dehydrogenase Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma. J Cancer. 2019; 10(16):3657-3664. PMC: 6636291. DOI: 10.7150/jca.32716. View

10.

Cheung F, Chan O, Ng W, Chan L, Lee A, Pang S . The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncol. 2011; 48(5):429-33. DOI: 10.1016/j.oraloncology.2011.11.017. View

11.

OuYang P, Su Z, Mao Y, Liang X, Liu Q, Xie F . Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer. 2013; 109(3):788-94. PMC: 3738126. DOI: 10.1038/bjc.2013.343. View

12.

OuYang P, Zhang L, Lan X, Xie C, Zhang W, Wang Q . The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer. 2015; 112(9):1554-61. PMC: 4453682. DOI: 10.1038/bjc.2015.70. View

13.

Larouche J, Berger F, Chassagne-Clement C, Ffrench M, Callet-Bauchu E, Sebban C . Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010; 28(12):2094-100. DOI: 10.1200/JCO.2009.24.5860. View

14.

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

15.

Vigano L, Capussotti L, Lapointe R, Barroso E, Hubert C, Giuliante F . Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol. 2013; 21(4):1276-86. DOI: 10.1245/s10434-013-3421-8. View

16.

Tang L, Li C, Li J, Chen W, Chen Q, Yuan L . Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2015; 108(1). DOI: 10.1093/jnci/djv291. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio G . Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006; 243(2):229-35. PMC: 1448919. DOI: 10.1097/01.sla.0000197706.21803.a1. View

19.

Li F, Chen F, Chen Y, Chen Y, He X, Huang X . Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma. Front Oncol. 2020; 10:1469. PMC: 7479816. DOI: 10.3389/fonc.2020.01469. View

20.

Chen Y, Zhao B, Chen C, Lei X, Shen L, Chen G . Alcohol drinking as an unfavorable prognostic factor for male patients with nasopharyngeal carcinoma. Sci Rep. 2016; 6:19290. PMC: 4725964. DOI: 10.1038/srep19290. View